Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease

Hepatitis C virus (HCV) prevalence inchronic kidney disease (CKD) patients is significantly higher than in the general population. This study evaluated the efficacy and safety of combined ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with renal impairment. Our study included 829 pa...

Full description

Saved in:

Bibliographic Details
Published in:	Arab journal of gastroenterology Vol. 24; no. 1; pp. 29 - 33
Main Authors:	El-Sayed, Mohammad, Elserafy, Magdy, El Raziky, Maissa, Elakel, Wafaa, Saad, Yasmin, Fayad, Tarek, Korany, Mohamed, Mehrez, Mai, Salama, Rabab, Mahrous, Maged, Zaki, Ayman, Hassany, Mohamed, Ammar, Islam, Elsaeed, Kadry, Elshazly, Yehia, Doss, Wahid
Format:	Journal Article
Language:	English
Published:	Egypt Elsevier B.V 01-02-2023
Subjects:	Anilides - adverse effects Antiviral Agents - adverse effects Carbamates - adverse effects Chronic kidney disease Drug Therapy, Combination Genotype HCV Hepacivirus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Humans Macrocyclic Compounds - adverse effects Macrocyclic Compounds - therapeutic use Ombitasvir/paritaprevir/ritonavir Renal Insufficiency, Chronic - chemically induced Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Ribavirin - adverse effects Ritonavir - adverse effects Treatment Outcome Valine - therapeutic use HCV Chronic kidney disease Ombitasvir/paritaprevir/ritonavir
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Hepatitis C virus (HCV) prevalence inchronic kidney disease (CKD) patients is significantly higher than in the general population. This study evaluated the efficacy and safety of combined ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with renal impairment. Our study included 829 patients with normal kidney functions (group 1) and 829 patients with CKD (group 2),which were subdivided into patients not requiring dialysis (group 2a) and those on hemodialysis (group2b). Patients received regimens of ombitasvir/paritaprevir/ritonavir with or without ribavirin or sofosbuvir/ombitasvir/paritaprevir/ritonavir with or without ribavirin for 12 weeks. Clinical and laboratory assessment was done before treatment, and patients were followed up for12 weeks after treatment. The sustained virological response (SVR) at week 12 was significantly higher in group 1 than in the other three groups/subgroups, being 94.2% vs 90.2%, 90%, and 90.7%, respectively. The regimen with the highest SVR was ombitasvir/paritaprevir/ritonavir with ribavirin. The most common adverse event was anemia, which was more common in group 2. Ombitasvir/paritaprevir/ritonavir-based therapy in chronic HCV patients with CKD is highly effective, with minimal side effects despite ribavirin-induced anemia.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1687-1979 2090-2387
DOI:	10.1016/j.ajg.2022.10.001